Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine

The rapid spread of the COVID-19 pandemic, with its devastating medical and economic impacts, triggered an unprecedented race toward development of effective vaccines. The commercialized vaccines are parenterally administered, which poses logistic challenges, while adequate protection at the mucosal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitcovski, Jacob, Gruzdev, Nady, Abzach, Anna, Katz, Chen, Ben-Adiva, Ran, Brand-Shwartz, Michal, Yadid, Itamar, Ratzon-Ashkenazi, Einav, Emquies, Ken, Israeli, Hadasa, Haviv, Hadar, Rapoport, Irena, Bloch, Itai, Shadmon, Roy, Eitan, Zohar, Eliahu, Dalia, Hilel, Talia, Laster, Morris, Kremer-Tal, Sigal, Byk-Tennenbaum, Tamara, Shahar, Ehud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768024/
https://www.ncbi.nlm.nih.gov/pubmed/35078662
http://dx.doi.org/10.1016/j.vaccine.2022.01.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768024/
https://www.ncbi.nlm.nih.gov/pubmed/35078662
http://dx.doi.org/10.1016/j.vaccine.2022.01.025

Ejemplares similares